Advisory Alpha LLC Buys 417 Shares of Eli Lilly and Company $LLY

Key Points

• Advisory Alpha LLC has increased its stake in Eli Lilly and Company ($LLY) by 11.1% during the first quarter, now owning 4,168 shares valued at approximately $3.44 million.
• In a recent quarter, insider buying included purchases from Director Gabrielle Sulzberger and CEO David A. Ricks, acquiring 117 and 1,632 shares respectively, reflecting growing confidence in the company's future.
• Eli Lilly's latest earnings report revealed an EPS of $6.31, exceeding estimates, with quarterly revenue reaching $15.56 billion, up 37.6% compared to last year.

Advisory Alpha LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,168 shares of the company's stock after buying an additional 417 shares during the quarter. Advisory Alpha LLC's holdings in Eli Lilly and Company were worth $3,442,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. WestEnd Advisors LLC increased its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $27,000. Citizens National Bank Trust Department increased its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $43,000. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 1.6%

Shares of Eli Lilly and Company stock opened at $738.58 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $942.35. The business has a fifty day simple moving average of $743.02 and a 200 day simple moving average of $779.63. The stock has a market cap of $699.04 billion, a PE ratio of 48.27, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.